Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.4959
-0.0342 (-6.45%)
At close: Dec 5, 2025, 4:00 PM EST
0.4974
+0.0015 (0.30%)
After-hours: Dec 5, 2025, 7:59 PM EST
Sangamo Therapeutics Revenue
Sangamo Therapeutics had revenue of $581.00K in the quarter ending September 30, 2025, a decrease of -98.82%. This brings the company's revenue in the last twelve months to $32.88M, down -37.13% year-over-year. In the year 2024, Sangamo Therapeutics had annual revenue of $57.80M, down -67.20%.
Revenue (ttm)
$32.88M
Revenue Growth
-37.13%
P/S Ratio
3.74
Revenue / Employee
$179,645
Employees
183
Market Cap
166.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 57.80M | -118.43M | -67.20% |
| Dec 31, 2023 | 176.23M | 64.93M | 58.34% |
| Dec 31, 2022 | 111.30M | 598.00K | 0.54% |
| Dec 31, 2021 | 110.70M | -7.49M | -6.34% |
| Dec 31, 2020 | 118.19M | 15.76M | 15.39% |
| Dec 31, 2019 | 102.43M | 17.98M | 21.29% |
| Dec 31, 2018 | 84.45M | 47.89M | 130.95% |
| Dec 31, 2017 | 36.57M | 17.18M | 88.60% |
| Dec 31, 2016 | 19.39M | -20.15M | -50.96% |
| Dec 31, 2015 | 39.54M | -6.33M | -13.80% |
| Dec 31, 2014 | 45.87M | 21.74M | 90.07% |
| Dec 31, 2013 | 24.13M | 2.48M | 11.44% |
| Dec 31, 2012 | 21.66M | 11.34M | 109.86% |
| Dec 31, 2011 | 10.32M | -10.49M | -50.40% |
| Dec 31, 2010 | 20.81M | -1.38M | -6.23% |
| Dec 31, 2009 | 22.19M | 6.00M | 37.08% |
| Dec 31, 2008 | 16.19M | 7.09M | 77.91% |
| Dec 31, 2007 | 9.10M | 1.21M | 15.38% |
| Dec 31, 2006 | 7.89M | 5.40M | 217.43% |
| Dec 31, 2005 | 2.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SGMO News
- 4 days ago - Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy - GlobeNewsWire
- 15 days ago - Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease - GlobeNewsWire
- 4 weeks ago - Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call - GlobeNewsWire
- 3 months ago - Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025 - GlobeNewsWire
- 4 months ago - Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results - GlobeNewsWire